Compare TRUP & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | GLPG |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.1B |
| IPO Year | 2014 | 2005 |
| Metric | TRUP | GLPG |
|---|---|---|
| Price | $36.41 | $31.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $56.33 | $31.33 |
| AVG Volume (30 Days) | ★ 427.8K | 111.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,399,759,000.00 | $336,643,201.00 |
| Revenue This Year | $14.02 | $3.61 |
| Revenue Next Year | $9.35 | N/A |
| P/E Ratio | $100.91 | ★ N/A |
| Revenue Growth | ★ 12.50 | 10.31 |
| 52 Week Low | $31.00 | $22.36 |
| 52 Week High | $57.89 | $37.78 |
| Indicator | TRUP | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 51.01 |
| Support Level | $33.68 | $31.41 |
| Resistance Level | $38.70 | $32.75 |
| Average True Range (ATR) | 1.33 | 0.51 |
| MACD | 0.36 | 0.16 |
| Stochastic Oscillator | 54.79 | 51.23 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.